Theravance Biopharma, Inc.
Theravance Biopharma discovers, develops, and commercializes respiratory medicines in the US and Europe. They offer YUPELRI for COPD treatment and Ampreloxetine, an investigational drug for neurogenic orthostatic hypotension. They also have TRELEGY for COPD and asthma treatment. The company has agreements with Pfizer and Viatris.
Overview
Strengths
- With an appreciation Potential of 161.38%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (8.04) is lower than the sector mean (91.15).
- Price to book ratio (2.87) is lower than the sector mean (24.44).
- The company has high returns. ROIC (70.28%) is higher than the sector mean (6.02%).
- EV/EBIT (5.51) is lower than the sector mean.
- Price to free cash flow (3.57) is lower than the sector mean.
- Strong EBITDA Margin of 55.26%.
Weaknesses
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
Key Financial Data